Histone methyltransferase and drug resistance in cancers
Histone methyltransferase and drug resistance in cancers
复制标题
DOI：
10.1186/s13046-020-01682-z
复制
发表时间：
2020-08
期刊：
影响因子：
--
通讯作者：
Cheng Yang;Jiayu Zhang;Yukui Ma;Chunfu Wu;Wei Cui;Lihui Wang
中科院分区：
文献类型：
--
作者：
Cheng Yang;Jiayu Zhang;Yukui Ma;Chunfu Wu;Wei Cui;Lihui Wang
近年来已开发出多种新型抗癌药物。然而，由于耐药性的出现，癌症患者的死亡率仍然很高。据报道，耐药性可能涉及基因表达的变化而不改变基因型，这与表观遗传修饰类似。一些研究表明，靶向组蛋白甲基转移酶可以逆转耐药性。因此，组蛋白甲基转移酶抑制剂或组蛋白去甲基化酶抑制剂的使用为癌症治疗开辟了新的治疗方法。虽然组蛋白甲基转移酶与肿瘤耐药性之间的关系已经确定，但缺乏对它们之间关联的最新综述。在这篇综述中，我们总结了组蛋白甲基转移酶在癌症耐药中的机制以及靶向组蛋白甲基转移酶逆转耐药的治疗策略。
A number of novel anticancer drugs have been developed in recent years. However, the mortality of cancer patients remains high because of the emergence of drug resistance. It was reported that drug resistance might involved in changes in gene expression without changing genotypes, which is similar to epigenetic modification. Some studies indicated that targeting histone methyltransferase can reverse drug resistance. Hence, the use of histone methyltransferase inhibitors or histone demethylase inhibitors opens new therapeutic approaches for cancer treatment. While the relationship between histone methyltransferase and tumor resistance has been determined, there is a lack of updated review on the association between them. In this review, we summarized the mechanisms of histone methyltransferases in cancer drug resistance and the therapeutic strategies of targeting histone methyltransferase to reverse drug resistance.